Details

Autor(en) / Beteiligte

• Birsen, Rudy
• Blanc, Estelle
• Willems, Lise
• Burroni, Barbara
• Legoff, Marielle
• Le Ray, Emmanuelle
• Pilorge, Sylvain
• Salah, Sawsen
• Quentin, Aude
• Deau, Benedicte
• Franchi, Patricia
• Vignon, Marguerite
• Mabille, Laurence
• Nguyen, Charles
• Kirova, Yioula
• Varlet, Pascale
• Edjlali, Myriam
• Dezamis, Edouard
• Hoang-Xuan, Khê
• Soussain, Carole
• Houillier, Caroline
• Damotte, Diane
• Pallud, Johan
• Bouscary, Didier
• Tamburini, Jerome

Titel

Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients

Ist Teil von

• Oncotarget, 2018-03, Vol.9 (24), p.16822-16831

Ort / Verlag

United States: Impact Journals LLC

Erscheinungsjahr

2018

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Primary central nervous system lymphoma (PCNSL) is a rare topographic variant of diffuse large B-cell lymphoma (DLBCL). While prognostic scales are useful in clinical trials, no dynamic prognostic marker is available in this disease. We report here the prognostic value of early metabolic response by 18F-FDG PET scanner (PET) in 25 newly diagnosed immunocompetent PCNSL patients. Induction treatment consisted of four cycles of Rituximab, Methotrexate and Temozolamide (RMT). Based on patient's general condition, consolidation by high-dose Etoposide and Aracytine was given to responding patients. Brain MRI and PET were performed at diagnosis, after two and four cycles of RMT, and after treatment completion. Two-year progression-free (PFS) and overall survival (OS) were 62% and 74%, respectively for the whole cohort. Best responses after RMT induction were 18 (72%) complete response (CR)/CR undetermined (CRu), 4 (16%) partial response, 1 (4%) progressive disease and 2 (8%) stable disease. Response evaluation was concordant between MRI and PET at the end of induction therapy. Nineteen patients (76%) had a negative PET2. Predictive positive and negative values of PET2 on end-of-treatment (ETR) CR were 66.67% and 94.74%, respectively. We observed a significant association between PET2 negativity and ETR ( = 0.001) and longer PFS ( = 0.02), while having no impact on OS ( = 0.32). Two years PFS was 72% and 33% for PET2- and PET2+ patients, respectively ( < 0.02). PET2 evaluation may help to early define a subgroup of CR PCNSL patients with a favorable outcome.